Towards the development of small molecule MO25-binders as potential indirect SPAK/OSR1 kinase inhibitors

Kadri, Hachemi, Alamri, Mubarak A., Navratilova, Iva H., Alderwick, Luke J., Simpkins, Nigel S. and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2017. Towards the development of small molecule MO25-binders as potential indirect SPAK/OSR1 kinase inhibitors. ChemBioChem 18 (5) , pp. 460-465. 10.1002/cbic.201600620

Preview

PDF - Accepted Post-Print Version Download (1MB) | Preview

Abstract

The binding of the scaffolding protein MO25 to SPAK and OSR1 protein kinases, which regulate ion homeostasis, causes up to 100-fold increase in their catalytic activity. Since various animal models showed that the inhibition of SPAK and OSR1 lowers blood pressure, we herein present a novel indirect approach for inhibiting SPAK and OSR1 kinases by targeting their protein partner MO25. To explore this approach, we developed fluorescent polarization assay and used it in screening a small in-house library of  4,000 compounds. This led to the identification of one molecule, HK01, as the first small molecule inhibitor of the MO25-dependent activation of SPAK and OSR1 in vitro. Our data confirms the feasibility of targeting this protein-protein interaction by small molecules and highlights the potential of these molecules to modulate ion cotransporters and thus cellular electrolyte balance.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Subjects:	R Medicine > RS Pharmacy and materia medica
Uncontrolled Keywords:	MO25; Scaffolding; inhibitor; SPAK; OSR1
Publisher:	Wiley
ISSN:	1439-4227
Date of First Compliant Deposit:	4 January 2017
Date of Acceptance:	22 December 2016
Last Modified:	15 Nov 2024 14:45
URI:	https://orca.cardiff.ac.uk/id/eprint/97175

Citation Data

Cited 7 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item